

Amendments to the Specification

Page 24, line 8-9, please rewrite as follows:

(5) 1-[3-(2-(2-thienylmethyl)phenoxy)-2-hydroxypropyl]-4-(4-pyridylcarbamoyl)piperidine

Page 25, lines 30-31, please rewrite as follows:

(44) 1 4-[N-(2-pyridyl)-N-(2-(N,N-dimethylamino)ethyl)carbamoyl]piperidine

Page 37, lines 2-11, please rewrite as follows:

Formulation Example 2 : Capsules

compound of the present invention	10.0	mg
Lactose	70.0	mg
Corn starch	35.0	mg
cellulose	29.7	mg
Polyvinylpyrrolidone K30	2.0	mg
Talc	2.7	mg
Magnesium stearate	0.3	mg
<hr/>		
	120.0	mg